New cancer drug's effect on common meds tested in small early trial
NCT ID NCT07372625
First seen Jan 30, 2026 · Last updated Apr 29, 2026 · Updated 13 times
Summary
This early-phase study looks at how a new drug called rezatapopt affects the way the body processes four common medicines (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific TP53 Y220C mutation. About 14 participants will take rezatapopt along with these other drugs to measure changes in drug levels and safety. The goal is to understand potential drug interactions, not to treat the cancer directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
Contact Email: •••••@•••••
-
HealthOne Denver
RECRUITINGDenver, Colorado, 80237, United States
Contact Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
-
SCRI at Mary Crowley
RECRUITINGDallas, Texas, 75230, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.